Select Merck and KEYTRUDA® (pembrolizumab) Data Presentations at 2017 ASCO Annual Meeting

A select listing of abstracts involving Merck and KEYTRUDA® (pembrolizumab) studies at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) are listed below. Overall, researchers will present data investigating KEYTRUDA across 16 types of cancer, both as monotherapy and in combination with other therapies – including data from Merck’s strategic clinical collaborations with Incyte, Eli Lilly & Co., Dynavax Technologies, Syndax, Viralytics, GlaxoSmithKline and Eisai across a wide variety of tumors and various stages of disease.

For more information, including full abstracts, please visit the ASCO iPlanner website at https://iplanner.asco.org/am2017/#/.

**BLADDER CANCER**

**Combination Studies**

**Monotherapy Studies**
- Abstract #4530 **Poster Session**: Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045. R. De Wit. Sunday, June 4. 8:00 a.m. -11:30 a.m. CDT. Location: Hall A.
- Abstract #4501 **Oral Session**: Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). D. Bajorin. Monday, June 5. 8:12 a.m. - 8:24 a.m. CDT. Location: Arie Crown Theater.
- Abstract #4502 **Oral Session**: Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). P. O'Donnell. Monday, June 5. 8:24 a.m. - 8:36 a.m. CDT. Location: Arie Crown Theater.

**BREAST AND GYNECOLOGIC CANCERS**

**Combination Studies**
- Abstract #5598 **Poster Session**: A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. V. Makker. Saturday, June 3. 1:15 p.m. - 4:45 p.m. CDT. Location: Hall A.
- Abstract #556 **Poster Session**: Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. P. Schmid. Sunday, June 4. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.
- Abstract #1103 **Poster Session**: Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase III ECHO-202 study. A. Spira. Sunday, June 4. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.
- Abstract #506 **Oral Session**: Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. R. Nanda. Monday, June 5. 11:45 a.m. - 11:57 a.m. CDT. Location: Hall D2.
Monotherapy Studies

- Abstract #5513 Poster Session/Discussion: Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. A. Varga. Saturday, June 3. Poster: 1:15 p.m. - 4:45 p.m. CDT. Location: Hall A. Discussion: 4:45 p.m. - 6:00 p.m. CDT. Location: Arie Crown Theater.

- Abstract #5514 Poster Session/Discussion: Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. J. Schellens. Saturday, June 3. Poster: 1:15 p.m. - 4:45 p.m. CDT. Location: Hall A. Discussion: 4:45 p.m. - 6:00 p.m. CDT. Location: Arie Crown Theater.

- Abstract #1008 Oral Session: Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. S. Adams. Saturday, June 3. 3:39 p.m. - 3:51 p.m. CDT. Location: Hall D1.

- Abstract #1088 Poster Session: Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. S. Adams. Sunday, June 4. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.

GASTROINTESTINAL CANCER

Combination Studies

- Abstract #4012 Poster Session/Discussion: KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. YJ. Bang. Saturday, June 3. Poster: 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A. Discussion: 4:45 p.m. - 6:00 p.m. CDT. Location: Hall D2.

- Abstract #4046 Poster Session: Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. I. Chau. Saturday, June 3. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.

Monotherapy Studies

- Abstract #4003 Oral Session: KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. C. Fuchs. Sunday, June 4. 9:00 a.m. - 9:12 a.m. CDT. Location: Hall D2.

HEAD AND NECK CANCER

Combination Studies

- Abstract #6010 Clinical Science Symposium: Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase I/II results from ECHO-202/KEYNOTE-037. O. Hamid. Tuesday, June 6. 8:12 a.m. - 8:24 a.m. CDT. Location: S100a.

Monotherapy Studies

- Abstract #6009 Clinical Science Symposium: Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). R. Haddad. Tuesday, June 6. 8:00 a.m. - 8:12 a.m. CDT. Location: S100a.

LUNG CANCER

Combination Studies

- Abstract #9014 Poster Session/Discussion: Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037. T. Gangadhar. Saturday, June 3. Poster: 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A. Discussion: 3:00 p.m. - 4:15 p.m. CDT. Location: Hall D2.
• **Abstract #9094 Poster Session:** First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. V. Papadimitrakopoulou. Saturday, June 3. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.

**Monotherapy Studies**

• **Abstract #9090 Poster Session:** Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. R. Herbst. Saturday, June 3. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.

• **Abstract #9011 Poster Session/Discussion:** KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. N. Leighl. Saturday, June 3. Poster: 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A. Discussion: 3:00 p.m. - 4:15 p.m. CDT. Location: Hall D2.

• **Abstract #9000 Oral Session:** Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. J. Brahmer. Tuesday, June 6. 9:45 a.m. - 9:57 a.m. CDT. Location: Hall D1.

**MELANOMA**

**Combination Studies**

• **Abstract #9529 Poster Session:** ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma. M. L. Johnson. Saturday, June 3. 1:15 p.m. - 4:45 p.m. CDT. Location: Hall A.

• **Abstract #9550 Poster Session:** Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients. A. Leung. Saturday, June 3. 1:15 p.m. - 4:45 p.m. CDT. Location: Hall A.

• **Abstract #9545 Poster Session:** KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. M. Carlino. Saturday, June 3. 1:15 p.m. - 4:45 p.m. CDT. Location: Hall A.

**Monotherapy Studies**

• **Abstract #9539 Poster Session:** Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression. Y. Jansen. Saturday, June 3. 1:15 p.m. - 4:45 p.m. CDT. Location: Hall A.

• **Abstract #9504 Oral Session:** Long-term outcomes in patients (pts) with ipilimumab (ipi)-naïve advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. C. Robert. Sunday, June 4. 9:12 a.m. - 9:24 a.m. CDT. Location: Arie Crown Theater.

• **Abstract #10525 Poster Session/Discussion:** Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed, or refractory solid tumor or lymphoma. B. Geoerger. Sunday, June 4. Poster: 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A. Discussion: 11:30 a.m. - 12:45 p.m. CDT. Location: S504.

**MICROSATELLITE INSTABILITY-HIGH (MSI-H) CANCER**

**Monotherapy Studies**

• **Abstract #3071 Poster Session:** Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. L. Diaz. Monday, June 5. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.
RENNAL CELL CARCINOMA (RCC)

Combination Studies

- **Abstract #4515 Poster Session/Discussion**: Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037. P. Lara. Sunday, June 4. Poster: 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A. Discussion: 11:30 a.m. - 12:45 a.m. CDT. Location: Arie Crown Theater.

- **Abstract #4506 Oral Session**: A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). S. Chowdhury. Monday, June 5. 9:36 a.m. - 9:48 a.m. CDT. Location: Arie Crown Theater.

ADDITIONAL CANCERS

Combination Studies

- **Abstract #3012 Poster Session/Discussion**: Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037. O. Hamid. Monday, June 5. Session: 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A. Discussion: 4:45 p.m. - 6:00 p.m. CDT. Location: Hall D1.

- **Abstract #TPS3113 Poster Session**: INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. E. Angevin. Monday, June 5. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.

- **Abstract #8015 Poster Session/Discussion**: Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses. E. Ocio. Monday, June 5. Poster: 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A. Discussion: 3:00 p.m. - 4:15 p.m. CDT. Location: E354b.

- **Abstract #TPS3108 Poster Session**: Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients. H. Pandha. Monday, June 5. 8:00 a.m. - 11:30 a.m. CDT. Location: Hall A.

For additional information on Merck, visit www.mercknewsroom.com/oncology-infocenter. Investigator-initiated / investigator-sponsored studies not included in this document.